All Boards >> Irritable Bowel Syndrome Research Library

View all threads Posts     Flat     Threaded

Antibiotics Early in Life May Boost Obesity Risk
      08/18/14 03:13 PM

Reged: 12/09/02
Posts: 7799
Loc: Seattle, WA

Antibiotics Early in Life May Boost Obesity Risk

Published: Aug 17, 2014
By Salynn Boyles, Contributing Writer, MedPage Today
Reviewed by F. Perry Wilson, MD, MSCE; Instructor of Medicine, Perelman School of Medicine at the University of Pennsylvania

Exposure to antibiotics early in life may permanently alter gut microbes in a way that could increase obesity risk years later, researchers reported.

In a study that compared outcomes in mice given low-dose penicillin versus those who were not, infancy was identified as a critical window of host-microbe metabolic interaction, suggesting that early-life antibiotic exposure can lead to lifelong metabolic changes, wrote Martin Blaser, MD, of NYU Langone Medical Center in New York City, and colleagues in the Aug. 14 issue of Cell.

This new finding expands on previous research by Blaser's group that tied antibiotic treatment from birth to accelerated growth in mice.

"We showed that the earlier we gave the antibiotic, the stronger the effect, and when we combined antibiotics with a high-fat diet the effect was potentiated and the mice got very fat," Blaser told MedPage Today. "We also showed that the metabolic effects remained when antibiotics were given for just 4 weeks in infancy, suggesting that early life exposure can have lifelong effects."

The Antibiotic-Obesity Link

Early life has been shown to be a critical period for metabolic development, and several epidemiological studies suggested a link between early antibiotic exposure to an increase in overweight status later in childhood, the researchers wrote.

Earlier this month, a study published in the International Journal of Obesity found exposure to antibiotics during the first year of life to be associated with a small increase in body mass index (BMI) in boys between the ages of 5 and 12, but not girls.

Blaser's team has studied the impact of antibiotic use on animal and human microbiome and how microbiome alteration impacts health for several years.

Microbes begin to colonize in the gut at birth, and Blaser and colleagues hypothesized that disruption of these communities with antibiotics early in life have long-term effects on weight and the risk for diseases associated with obesity, such as diabetes.

"For decades, farmers have been exposing livestock to low doses of antibiotics to promote growth; the earlier in life that exposure begins the more profound the effects," they wrote.

For the current study, they examined antibiotic exposure timing in an effort to determine if a critical window of exposure exists. They also addressed whether synergies exist between antibiotic exposure and dietary effects, and whether microbiota alterations are sufficient to impact metabolic phenotypes.

"Hypothesizing that early life was the critical period for programming host-microbe metabolic interactions, we sought to determine whether microbiota disruption limited to early life could induce metabolic effects," the researchers wrote. "In addition to long-term (28 week) low-dose penicillin (LDP) or none (control), groups of mice received 4 or 8 weeks of LDP, and to accelerate metabolic phenotypes, all were switched to high-fat diet (HFD) at 6 weeks of age."

Penicillin Altered Ileal Tissue

In female mice, all three low-dose penicillin groups developed elevated total, lean, and fat mass compared to controls, irrespective of low-dose penicillin duration. Compared to controls, following switch to high-fat diet, female low-dose penicillin mice had significantly elevated caloric intake and significantly faster total and fat mass accumulation rates from 6 to 20 weeks of age.

Later in life (weeks 20-28), all three low-dose penicillin groups showed significantly slower rates in lean mass growth compared to controls, indicating catch-up by the control mice.

Male mice on low-dose penicillin showed early elevations in total, lean, and fat mass but did not have increased food intake or feed efficiency from 6 to 8 weeks of age. The early-life changes in body composition were lost with age, which was consistent with an earlier reported increased early-life and gender-dependent sensitivity to high-fat diet that may override microbe-mediated effects, the researchers noted.

"By age 4 weeks, LDP induced substantial histopathologic effects in ileal tissues, notably shortened villi, which is consistent with changed ileal architecture in LDP-mediated livestock growth promotion," the researchers wrote. "Transcriptional profiling analysis of intestinal tissue by microarray and subsequent validation by Nanostring analysis revealed that the ileal atrophy from LDP was associated with a general decreased expression of genes involved in intestinal immune responses, with numerous consistencies across gender."

"Low-dose penicillin decreased expression of genes related to several biological functions, such as differentiation, activation, recruitment, and adhesion of immune cells, and functions specifically related to androgen-presenting cells, T cells, B cells and phagocytic cells," they explained.

High-Fat Diet Exacerbated Changes

Antibiotic exposure also induced numerous compositional changes in the microbiota, and introduction of the high-fat diet had further effects. After antibiotics were stopped in the mice given low-dose penicillin for both 4 and 8 weeks, the patterns associated with high-fat diet exposure of the control mice began to emerge, the group stated, but were never present in mice exposed to 28 weeks of low-dose penicillin.

"The persistent phenotypes after LDP cessation, despite microbiota normalization, provide evidence that the early-life microbiota influences adult body composition," the researchers wrote.

Low-dose penicillin suppressed early-life Lactobacillus, Allobaculum, Rikenellaceae, and Candidatus Arthromitus. This finding suggests a protective role for these organisms in the modulation of host metabolism.

"All microbiota members do not equally impact the host; prior studies indicate that these four organisms have either metabolic and/or immunologic interactions which may contribute to the observed protection from weight gain in the control animals," the researchers wrote.

Future Plans

Blaser's team is currently conducting research designed to determine if re-introducing these bacteria following antibiotic therapy will impact weight gain.

"Our findings imply that restoring good bacteria could prevent the long-term metabolic effects of early antibiotic exposure," stated co-author Laura M. Cox, PhD, in an accompanying statement.

Blaser said some combination of these bacteria or others that have not yet been identified could prove critical in early-life metabolic protection.

He added that the research team is also investigating the impact of early antibiotic use on diabetes risk.

In a prospective study reported earlier this summer, a different group of researchers showed that composition of gut bacteria in patients with type 2 diabetes differed from those of people without the disease.

Obese patients and those with diabetes had lower proportions of the bacteria Firmicutes, Bifidobacteria, and Clostridium Leptum, compared to healthy controls, Yalcin Basaran, MD, of Gulhane Military Medical Academy in Ankara, Turkey, and colleagues reported at the joint meeting of the Endocrine Society and the International Congress on Endocrinology in Chicago.

The analysis revealed that metabolic parameters such as weight (P<0.001), BMI (P<0.001), HbA1c (P=0.011), waist circumference (P<0.001), and fasting blood glucose (P=0.005) were significantly associated with reduced levels of these three types of bacteria in the gut.

Blaser said all of these studies point to an important developmental window early in life during which antibiotic exposure can have long-term effects on metabolism.

"We can't say what this window is, but the epidemiological studies have focused on the first year of life," he said. "Physicians need to know that antibiotics use could have long-term costs, and this needs to be factored into decisions about when to use them."

Heather is the Administrator of the IBS Message Boards. She is the author of Eating for IBS and The First Year: IBS, and the CEO of Heather's Tummy Care. Join her IBS Newsletter. Meet Heather on Facebook!

Print     Remind Me     Notify Moderator    

Entire thread
* Pharmaceutical
07/14/03 01:50 PM
* Medical Marijuana Significant for Migraines, Fibromyalgia, and IBS
02/16/21 01:21 PM
* Heartburn drugs that are proton pump inhibitors could trigger IBS and SIBO
12/07/20 01:28 PM
* For IBS Patients, Cannabis Linked to Fewer Rehospitalizations
05/05/20 02:14 PM
* Cannabis could help a person defecate
04/14/20 12:17 PM
* FDA OKs Reintroduction of Tegaserod (Zelnorm) for IBS-C in Women Under 65
04/04/19 02:45 PM
* Long-term cannabis use increases risk for IBS
10/19/17 04:04 PM
* FDA approves new drug for chronic constipation
01/26/17 03:05 PM
* Mixed Opioid Agent Adds to Growing List of Therapies for IBS-D
01/27/16 02:48 PM
* Low-dose naltreoxone for the treatment of irritable bowel syndrome
01/26/16 01:20 PM
* Amitiza benefited patients with chronic idiopathic constipation
02/10/15 04:15 PM
* Medical Marijuana for Digestive Disorders: High Time to Prescribe?
09/17/14 02:08 PM
* Antibiotics Early in Life May Boost Obesity Risk
08/18/14 03:13 PM
* Antidepressants, psychological therapies effectively treated IBS
07/15/14 02:49 PM
* Proton pump inhibitor (acid reflux drugs) may cause heart disease
09/23/13 03:22 PM
* Older drugs are better than new ones
06/13/13 02:00 PM
* On Anti-Depressants? Some Raise Risk of C. Diff Infection
05/13/13 05:51 PM
* Heartburn drugs, NSAID painkillers use linked to IBS symptoms
03/18/13 01:24 PM
* FDA approves Linzess to treat certain cases of irritable bowel syndrome and constipation
08/31/12 11:25 AM
* 3-month FDA delay for potential IBS drug linaclotide
04/23/12 01:45 PM
* Latest FDA watch list includes GI drugs
04/23/12 01:42 PM
* Antibiotics that reduce gut bacteria linked to obesity
05/06/11 12:25 PM
* Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases
02/10/11 10:23 AM
* Antacids increase risk of pneumonia
01/14/11 04:35 PM
* Editorial - Antibiotic Rifaximin (Xifaxan) Therapy for the Irritable Bowel Syndrome
01/07/11 03:01 PM
* Antiobiotic Rifaximin (Xifaxan) for Patients with Irritable Bowel Syndrome without Constipation
01/07/11 02:59 PM
* Proton Pump Inhibitor Drugs Tied to 80% Increase in Clostridium difficile Risk
11/10/10 11:29 AM
* Phase 3 clinical trials of linaclotide for IBS constipation
10/13/10 02:44 PM
* An over-the-counter drug for constipation offers superior symptom relief compared with a commonly used prescription agent
07/16/10 03:17 PM
* Benefit/risk ratio of Renzapride not sufficient to warrant further study in IBS-C
04/07/10 01:32 PM
* Adverse effects of drugs on small intestine and colon
03/16/10 11:23 AM
* Children's Belly Aches Don't Disappear With Antidepressant
03/11/10 01:14 PM
* Survey: Marijuana Use In Patients With IBS
01/12/10 03:17 PM
* FDA Approves Amitiza for IBS-C
05/23/08 10:59 AM
* Zelnorm no longer available except for emergency use
04/11/08 12:05 PM
* Clinical trial: phase 2 trial of lubiprostone for irritable bowel syndrome with constipation.
02/15/08 11:20 AM
* Role of Antibiotics vs Conventional Pharmacotherapy in Treating Symptoms of Irritable Bowel Syndrome
01/03/08 04:45 PM
* FDA permits the restricted use of Zelnorm
08/09/07 11:41 AM
* Antidepressant Therapy (Imipramine and Citalopram) for Irritable Bowel Syndrome
06/20/07 01:56 PM
* Neuromuscular Dysfunction and IBS: Clinical Implications for Drug Use
02/04/07 04:30 PM
* Enteric Bacteria and IBS
11/26/06 02:51 PM
* Rifaximin vs Placebo in Reducing Symptoms in Adults With IBS
11/26/06 02:39 PM
* Antibiotic Rifaximin Appears Safe and Effective for Irritable Bowel Syndrome
10/26/06 10:29 AM
* Citalopram (Celexa) Improves Symptoms of Irritable Bowel Syndrome
10/14/06 12:57 PM
* Marijuana eases chronic pain
07/17/06 11:49 AM
* Doctors group launches war on drug ads
07/17/06 11:17 AM
* New IBS drug in development in Japan
07/05/06 05:13 PM
* Marijuana and the gastrointestinal tract
06/12/06 03:38 PM
* Zelnorm Rejected Again in Europe
04/02/06 03:25 PM
* Antidepressants for IBS
03/16/06 12:31 PM
* Takeda Laxative Wins U.S. Approval for Adults
02/18/06 01:36 PM
* Cilansetron: ; Solvay Pharmaceuticals suspends registration activites in the U.S.,
01/18/06 04:15 PM
* Hearburn Drugs Cause Diarrhea
01/08/06 05:10 PM
* Zelnorm fails to win EU panel backing
12/21/05 11:25 AM
* Non-steroidal anti-inflammatory drugs and gastrointestinal damage
12/08/05 12:51 PM
* Octreotide May Be Effective in Treatment of Nonconstipated IBS
12/08/05 12:31 PM
* Lack of Lasting Effectiveness of Miralax Laxative Treatment of Constipation.
08/07/05 04:18 PM
* Acute Hepatitis Associated With Lotronex
07/24/05 02:37 PM
* FDA revisions to safety labeling for Lotronex (alosetron )
05/22/05 06:46 PM
* Clinical pharmacology of new motility promoting agents
05/22/05 06:33 PM
* Rationale for Using Serotonergic Agents to Treat Irritable Bowel Syndrome
05/08/05 06:21 PM
* Zelnorm Associated With Rare Cases of Severe Diarrhea, Ischemic Colitis
04/24/05 03:48 PM
* Clinical Response to Tricyclic Antidepressants in Functional Bowel Disorders not Related to Dosage
03/28/05 01:32 PM
* Efficacy and Safety of Alosetron in Men with Diarrhea-Predominant IBS
02/19/05 05:56 PM
* Irritable Bowel Syndrome Medications Side Effects Survey
11/09/04 02:04 PM
* On the Relationship Between Colon Ischemia, Irritable Bowel Syndrome, and Serotonergic Therapy of Irritable Bowel Syndrome
10/24/04 07:10 PM
* New Risk Information on Zelnorm for IBS for Women
07/11/04 02:18 PM
* The Relationship among Previous Antimicrobial Use and H. Pylori Infections
06/27/04 01:33 PM
* Therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome
06/04/04 03:54 PM
* Pharmaceutical companies funding a number of studies into IBS in the UK
05/25/04 12:00 PM
* Irritable bowel syndrome helped by Paroxetine, a drug for depression
05/10/04 02:15 PM
* Fears cause low sales of Lotronex
05/10/04 01:46 PM
* Zelnorm Warning Issued by FDA
05/10/04 01:01 PM
* Renzapride Improves Symptoms in Constipation-Predominant Irritable Bowel Syndrome
12/01/03 06:14 PM
* Clinical Trial Guidelines for Pharmacological Treatment of IBS - Pharmacological Options
12/01/03 05:55 PM
* SOLVAY presses ahead with cilansetron, a new IBS drug
11/18/03 03:43 PM
* Measuring Treatment Effects in IBS Trials
10/20/03 03:30 PM
* FDA Orders Novartis To Pull Zelnorm Ads
10/07/03 11:25 PM
* Step-down dosage of PPI drugs for hearburn
09/30/03 01:26 PM
* Evaluation of drug treatment in irritable bowel syndrome
09/30/03 12:52 PM
* Pain Relievers and Intestinal Disorders
09/16/03 04:20 PM
* Hypersensitivity and hyperreactivity in IBS: opportunity for drug discovery
07/18/03 12:39 PM
* Antidepressants in the Treatment of IBS and Other Functional GI Disorders
07/18/03 12:20 PM
* Use of Antidepressants in the Treatment of IBS?
07/14/03 03:58 PM
* Combined use of SSRIs and NSAIDs increases the risk of GI adverse effects
07/14/03 03:15 PM

Extra information
0 registered and 14 anonymous users are browsing this forum.

Moderator:  Heather 

      You cannot post until you login
      You cannot reply until you login
      HTML is enabled
      UBBCode is enabled

Thread views: 514585

Jump to

| Privacy statement Help for IBS Home

UBB.threads™ 6.2 BBB Business Review